Author:
Radeski Dejan,Cull Gavin M.,Cain Michael,Hackett L. Peter,Ilett Kenneth F.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference14 articles.
1. Lindner LH, Ostermann H, Hiddemann W et al (2008) AraU accumulation in patients with renal insufficiency as a potential mechanism for cytarabine neurotoxicity. Int J Hematol 88:381–386
2. Damon LE, Plunkett W, Linker CA (1991) Plasma and cerebrospinal fluid pharmacokinetics of 1-beta-D-arabinofuranosylcytosine and 1-beta-D-arabinofuranosyluracil following the repeated intravenous administration of high- and intermediate-dose 1-beta-D-arabinofuranosylcytosine. Cancer Res 51:4141–4145
3. Rubin EH, Andersen JW, Berg DT, Schiffer CA, Mayer RJ, Stone RM (1992) Risk factors for high-dose cytarabine neurotoxicity: an analysis of a cancer and leukemia group B trial in patients with acute myeloid leukemia. J Clin Oncol 10:948–953
4. Smith GA, Damon LE, Rugo HS, Ries CA, Linker CA (1997) High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. J Clin Oncol 15:833–839
5. Poschl JM, Klaus G, Querfeld U, Ludwig R, Mehls O (1993) Chemotherapy with cytosine arabinoside in a child with Burkitt’s lymphoma on maintenance hemodialysis and hemofiltration. Ann Hematol 67:37–39
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献